Cosmo and Glenmark receives UK MHRA approval to market Winlevi in UK

Glenmark USA launches Lacosamide Oral Solution, 10 mg/mL

According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million

Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP

This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers

Glenmark Pharma reports Q1 FY25 consolidated PAT at Rs. 340.2 Cr

India Business grew by 11.9% YoY to Rs. 1196.2 crore

Glenmark and IADVL undertake awareness campaign supporting vitiligo patients in India

Glenmark released Picture Post Cards on World Vitiligo Day

Glenmark and BeiGene ink agreement for marketing and distribution of Tislelizumab and Zanubrutinib in India

Glenmark receives ANDA approval for Brimonidine Tartrate and Timolol Maleate ophthalmic solution

According to IQVIATM sales data for the 12-month period ending March 2024, the Combigan Ophthalmic Solution, 0.2%|0.5% market achieved annual sales of approximately $290.0 million

Glenmark launches next phase of ‘India First Heart First’ campaign

35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases

Glenmark receives ANDA approval for acetaminophen and ibuprofen tablets

Glenmark’s Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC), will be distributed in the U.S. by Glenmark Therapeutics, USA

Nirma acquires majority stake in Glenmark Life Sciences

Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals